| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | peroxisome proliferator activated receptor binding | 2.85e-07 | 21 | 13 | 3 | GO:0042975 | |
| GeneOntologyMolecularFunction | peptide lactyltransferase (CoA-dependent) activity | 3.91e-07 | 2 | 13 | 2 | GO:0120300 | |
| GeneOntologyMolecularFunction | histone H3K27 acetyltransferase activity | 3.91e-07 | 2 | 13 | 2 | GO:0044017 | |
| GeneOntologyMolecularFunction | transcription coactivator activity | 9.07e-07 | 303 | 13 | 5 | GO:0003713 | |
| GeneOntologyMolecularFunction | histone H3K18 acetyltransferase activity | 1.17e-06 | 3 | 13 | 2 | GO:0043993 | |
| GeneOntologyMolecularFunction | transcription coregulator binding | 1.58e-06 | 140 | 13 | 4 | GO:0001221 | |
| GeneOntologyMolecularFunction | histone acetyltransferase activity | 4.41e-06 | 51 | 13 | 3 | GO:0004402 | |
| GeneOntologyMolecularFunction | transcription coactivator binding | 5.25e-06 | 54 | 13 | 3 | GO:0001223 | |
| GeneOntologyMolecularFunction | peptide-lysine-N-acetyltransferase activity | 5.55e-06 | 55 | 13 | 3 | GO:0061733 | |
| GeneOntologyMolecularFunction | peptide N-acetyltransferase activity | 7.22e-06 | 60 | 13 | 3 | GO:0034212 | |
| GeneOntologyMolecularFunction | molecular adaptor activity | 7.82e-06 | 1356 | 13 | 7 | GO:0060090 | |
| GeneOntologyMolecularFunction | N-acetyltransferase activity | 1.59e-05 | 78 | 13 | 3 | GO:0008080 | |
| GeneOntologyMolecularFunction | transcription coregulator activity | 1.85e-05 | 562 | 13 | 5 | GO:0003712 | |
| GeneOntologyMolecularFunction | SMAD binding | 2.14e-05 | 86 | 13 | 3 | GO:0046332 | |
| GeneOntologyMolecularFunction | N-acyltransferase activity | 3.57e-05 | 102 | 13 | 3 | GO:0016410 | |
| GeneOntologyMolecularFunction | acetyltransferase activity | 3.78e-05 | 104 | 13 | 3 | GO:0016407 | |
| GeneOntologyMolecularFunction | histone H3 acetyltransferase activity | 4.09e-05 | 15 | 13 | 2 | GO:0010484 | |
| GeneOntologyMolecularFunction | protein-macromolecule adaptor activity | 4.57e-05 | 1160 | 13 | 6 | GO:0030674 | |
| GeneOntologyMolecularFunction | chromatin binding | 6.88e-05 | 739 | 13 | 5 | GO:0003682 | |
| GeneOntologyMolecularFunction | transcription factor binding | 7.52e-05 | 753 | 13 | 5 | GO:0008134 | |
| GeneOntologyMolecularFunction | RNA polymerase II-specific DNA-binding transcription factor binding | 1.15e-04 | 417 | 13 | 4 | GO:0061629 | |
| GeneOntologyMolecularFunction | chromatin DNA binding | 1.55e-04 | 167 | 13 | 3 | GO:0031490 | |
| GeneOntologyMolecularFunction | nuclear androgen receptor binding | 2.04e-04 | 33 | 13 | 2 | GO:0050681 | |
| GeneOntologyMolecularFunction | nuclear receptor binding | 2.16e-04 | 187 | 13 | 3 | GO:0016922 | |
| GeneOntologyMolecularFunction | bHLH transcription factor binding | 2.57e-04 | 37 | 13 | 2 | GO:0043425 | |
| GeneOntologyMolecularFunction | disordered domain specific binding | 2.86e-04 | 39 | 13 | 2 | GO:0097718 | |
| GeneOntologyMolecularFunction | histone modifying activity | 3.91e-04 | 229 | 13 | 3 | GO:0140993 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor binding | 4.14e-04 | 582 | 13 | 4 | GO:0140297 | |
| GeneOntologyMolecularFunction | acyltransferase activity, transferring groups other than amino-acyl groups | 4.38e-04 | 238 | 13 | 3 | GO:0016747 | |
| GeneOntologyMolecularFunction | nuclear receptor coactivator activity | 7.01e-04 | 61 | 13 | 2 | GO:0030374 | |
| GeneOntologyMolecularFunction | basal RNA polymerase II transcription machinery binding | 8.20e-04 | 66 | 13 | 2 | GO:0001099 | |
| GeneOntologyMolecularFunction | basal transcription machinery binding | 8.20e-04 | 66 | 13 | 2 | GO:0001098 | |
| GeneOntologyMolecularFunction | p53 binding | 1.11e-03 | 77 | 13 | 2 | GO:0002039 | |
| GeneOntologyMolecularFunction | acyltransferase activity | 1.22e-03 | 775 | 13 | 4 | GO:0016746 | |
| GeneOntologyMolecularFunction | promoter-specific chromatin binding | 1.29e-03 | 83 | 13 | 2 | GO:1990841 | |
| GeneOntologyMolecularFunction | damaged DNA binding | 1.32e-03 | 84 | 13 | 2 | GO:0003684 | |
| GeneOntologyMolecularFunction | modification-dependent protein binding | 7.67e-03 | 206 | 13 | 2 | GO:0140030 | |
| GeneOntologyMolecularFunction | transcription corepressor activity | 9.40e-03 | 229 | 13 | 2 | GO:0003714 | |
| GeneOntologyMolecularFunction | zinc ion binding | 1.81e-02 | 891 | 13 | 3 | GO:0008270 | |
| GeneOntologyBiologicalProcess | N-terminal peptidyl-lysine acetylation | 2.20e-06 | 4 | 13 | 2 | GO:0018076 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase II | 7.44e-06 | 1390 | 13 | 7 | GO:0045944 | |
| GeneOntologyBiologicalProcess | N-terminal protein amino acid acetylation | 4.38e-05 | 16 | 13 | 2 | GO:0006474 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to heat | 4.38e-05 | 16 | 13 | 2 | GO:1900034 | |
| GeneOntologyBiologicalProcess | nuclear receptor-mediated steroid hormone signaling pathway | 7.64e-05 | 136 | 13 | 3 | GO:0030518 | |
| GeneOntologyBiologicalProcess | stimulatory C-type lectin receptor signaling pathway | 9.21e-05 | 23 | 13 | 2 | GO:0002223 | |
| GeneOntologyBiologicalProcess | cellular response to lectin | 9.21e-05 | 23 | 13 | 2 | GO:1990858 | |
| GeneOntologyBiologicalProcess | response to lectin | 9.21e-05 | 23 | 13 | 2 | GO:1990840 | |
| GeneOntologyBiologicalProcess | steroid hormone receptor signaling pathway | 1.13e-04 | 155 | 13 | 3 | GO:0043401 | |
| GeneOntologyBiologicalProcess | peptidyl-lysine acetylation | 1.37e-04 | 28 | 13 | 2 | GO:0018394 | |
| GeneOntologyBiologicalProcess | N-terminal protein amino acid modification | 1.47e-04 | 29 | 13 | 2 | GO:0031365 | |
| GeneOntologyBiologicalProcess | CD4-positive, alpha-beta T cell lineage commitment | 1.69e-04 | 31 | 13 | 2 | GO:0043373 | |
| GeneOntologyBiologicalProcess | alpha-beta T cell lineage commitment | 1.91e-04 | 33 | 13 | 2 | GO:0002363 | |
| GeneOntologyBiologicalProcess | regulation of transforming growth factor beta receptor signaling pathway | 2.12e-04 | 192 | 13 | 3 | GO:0017015 | |
| GeneOntologyBiologicalProcess | positive regulation of cellular response to transforming growth factor beta stimulus | 2.16e-04 | 35 | 13 | 2 | GO:1903846 | |
| GeneOntologyBiologicalProcess | positive regulation of transforming growth factor beta receptor signaling pathway | 2.16e-04 | 35 | 13 | 2 | GO:0030511 | |
| GeneOntologyBiologicalProcess | CD4-positive or CD8-positive, alpha-beta T cell lineage commitment | 2.16e-04 | 35 | 13 | 2 | GO:0043369 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to transforming growth factor beta stimulus | 2.22e-04 | 195 | 13 | 3 | GO:1903844 | |
| GeneOntologyBiologicalProcess | nuclear receptor-mediated signaling pathway | 2.46e-04 | 202 | 13 | 3 | GO:0141193 | |
| GeneOntologyBiologicalProcess | face morphogenesis | 2.97e-04 | 41 | 13 | 2 | GO:0060325 | |
| GeneOntologyBiologicalProcess | T cell lineage commitment | 3.11e-04 | 42 | 13 | 2 | GO:0002360 | |
| GeneOntologyBiologicalProcess | stem cell population maintenance | 3.93e-04 | 237 | 13 | 3 | GO:0019827 | |
| GeneOntologyBiologicalProcess | cellular response to steroid hormone stimulus | 4.03e-04 | 239 | 13 | 3 | GO:0071383 | |
| GeneOntologyBiologicalProcess | head morphogenesis | 4.07e-04 | 48 | 13 | 2 | GO:0060323 | |
| GeneOntologyBiologicalProcess | maintenance of cell number | 4.18e-04 | 242 | 13 | 3 | GO:0098727 | |
| GeneOntologyBiologicalProcess | hormone-mediated signaling pathway | 4.28e-04 | 244 | 13 | 3 | GO:0009755 | |
| GeneOntologyBiologicalProcess | positive T cell selection | 4.96e-04 | 53 | 13 | 2 | GO:0043368 | |
| GeneOntologyBiologicalProcess | protein destabilization | 5.54e-04 | 56 | 13 | 2 | GO:0031648 | |
| GeneOntologyBiologicalProcess | transforming growth factor beta receptor signaling pathway | 6.14e-04 | 276 | 13 | 3 | GO:0007179 | |
| GeneOntologyBiologicalProcess | face development | 7.01e-04 | 63 | 13 | 2 | GO:0060324 | |
| GeneOntologyBiologicalProcess | body morphogenesis | 7.23e-04 | 64 | 13 | 2 | GO:0010171 | |
| GeneOntologyBiologicalProcess | protein acetylation | 8.16e-04 | 68 | 13 | 2 | GO:0006473 | |
| GeneOntologyBiologicalProcess | T cell selection | 8.40e-04 | 69 | 13 | 2 | GO:0045058 | |
| GeneOntologyBiologicalProcess | cellular response to transforming growth factor beta stimulus | 1.09e-03 | 336 | 13 | 3 | GO:0071560 | |
| GeneOntologyBiologicalProcess | response to transforming growth factor beta | 1.15e-03 | 343 | 13 | 3 | GO:0071559 | |
| GeneOntologyBiologicalProcess | cellular response to heat | 1.16e-03 | 81 | 13 | 2 | GO:0034605 | |
| GeneOntologyBiologicalProcess | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 1.19e-03 | 347 | 13 | 3 | GO:0090092 | |
| GeneOntologyBiologicalProcess | regulation of intracellular steroid hormone receptor signaling pathway | 1.33e-03 | 87 | 13 | 2 | GO:0033143 | |
| GeneOntologyBiologicalProcess | response to steroid hormone | 1.56e-03 | 381 | 13 | 3 | GO:0048545 | |
| GeneOntologyBiologicalProcess | cellular response to UV | 1.65e-03 | 97 | 13 | 2 | GO:0034644 | |
| GeneOntologyBiologicalProcess | chromatin organization | 1.85e-03 | 896 | 13 | 4 | GO:0006325 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to growth factor stimulus | 1.95e-03 | 412 | 13 | 3 | GO:0090287 | |
| GeneOntologyBiologicalProcess | innate immune response activating cell surface receptor signaling pathway | 2.00e-03 | 107 | 13 | 2 | GO:0002220 | |
| GeneOntologyBiologicalProcess | intracellular receptor signaling pathway | 2.00e-03 | 416 | 13 | 3 | GO:0030522 | |
| GeneOntologyBiologicalProcess | head development | 2.03e-03 | 919 | 13 | 4 | GO:0060322 | |
| GeneOntologyBiologicalProcess | protein acylation | 2.04e-03 | 108 | 13 | 2 | GO:0043543 | |
| GeneOntologyBiologicalProcess | positive regulation of protein localization to nucleus | 2.27e-03 | 114 | 13 | 2 | GO:1900182 | |
| GeneOntologyBiologicalProcess | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 2.31e-03 | 115 | 13 | 2 | GO:0090100 | |
| GeneOntologyBiologicalProcess | positive regulation of intracellular protein transport | 2.35e-03 | 116 | 13 | 2 | GO:0090316 | |
| GeneOntologyBiologicalProcess | transforming growth factor beta receptor superfamily signaling pathway | 2.43e-03 | 445 | 13 | 3 | GO:0141091 | |
| GeneOntologyBiologicalProcess | CD4-positive, alpha-beta T cell differentiation | 2.47e-03 | 119 | 13 | 2 | GO:0043367 | |
| GeneOntologyBiologicalProcess | response to heat | 2.55e-03 | 121 | 13 | 2 | GO:0009408 | |
| GeneOntologyBiologicalProcess | protein-DNA complex organization | 2.75e-03 | 999 | 13 | 4 | GO:0071824 | |
| GeneOntologyBiologicalProcess | cellular response to light stimulus | 2.94e-03 | 130 | 13 | 2 | GO:0071482 | |
| GeneOntologyBiologicalProcess | cell surface receptor protein serine/threonine kinase signaling pathway | 3.05e-03 | 482 | 13 | 3 | GO:0007178 | |
| GeneOntologyBiologicalProcess | response to organic cyclic compound | 3.28e-03 | 1048 | 13 | 4 | GO:0014070 | |
| GeneOntologyBiologicalProcess | CD4-positive, alpha-beta T cell activation | 4.04e-03 | 153 | 13 | 2 | GO:0035710 | |
| GeneOntologyBiologicalProcess | alpha-beta T cell differentiation | 4.25e-03 | 157 | 13 | 2 | GO:0046632 | |
| GeneOntologyBiologicalProcess | peptidyl-lysine modification | 4.52e-03 | 162 | 13 | 2 | GO:0018205 | |
| GeneOntologyBiologicalProcess | positive regulation of lymphocyte differentiation | 4.52e-03 | 162 | 13 | 2 | GO:0045621 | |
| GeneOntologyBiologicalProcess | positive regulation of intracellular transport | 4.52e-03 | 162 | 13 | 2 | GO:0032388 | |
| GeneOntologyBiologicalProcess | response to UV | 4.79e-03 | 167 | 13 | 2 | GO:0009411 | |
| GeneOntologyCellularComponent | transcription regulator complex | 3.81e-04 | 596 | 13 | 4 | GO:0005667 | |
| GeneOntologyCellularComponent | histone acetyltransferase complex | 1.51e-03 | 94 | 13 | 2 | GO:0000123 | |
| GeneOntologyCellularComponent | protein acetyltransferase complex | 1.84e-03 | 104 | 13 | 2 | GO:0031248 | |
| GeneOntologyCellularComponent | acetyltransferase complex | 2.02e-03 | 109 | 13 | 2 | GO:1902493 | |
| HumanPheno | Phobia | 4.54e-10 | 3 | 5 | 3 | HP:5200232 | |
| HumanPheno | Agoraphobia | 4.54e-10 | 3 | 5 | 3 | HP:0000756 | |
| HumanPheno | Aortic isthmus hypoplasia | 7.71e-07 | 2 | 5 | 2 | HP:0034227 | |
| HumanPheno | Plantar crease between first and second toes | 7.71e-07 | 2 | 5 | 2 | HP:0008107 | |
| HumanPheno | High axial triradius | 7.71e-07 | 2 | 5 | 2 | HP:0001042 | |
| HumanPheno | Humoral immunodeficiency | 2.31e-06 | 3 | 5 | 2 | HP:0005363 | |
| HumanPheno | Prominent nasal septum | 2.31e-06 | 3 | 5 | 2 | HP:0005322 | |
| HumanPheno | Radial deviation of thumb terminal phalanx | 2.31e-06 | 3 | 5 | 2 | HP:0005895 | |
| HumanPheno | Laryngeal cartilage malformation | 2.31e-06 | 3 | 5 | 2 | HP:0008752 | |
| HumanPheno | Trichiasis | 4.62e-06 | 4 | 5 | 2 | HP:0001128 | |
| HumanPheno | Widened distal phalanges | 4.62e-06 | 4 | 5 | 2 | HP:0006200 | |
| HumanPheno | Visceral hemangioma | 4.62e-06 | 4 | 5 | 2 | HP:0410266 | |
| HumanPheno | Talon cusp | 4.62e-06 | 4 | 5 | 2 | HP:0011087 | |
| HumanPheno | Vascular ring | 4.62e-06 | 4 | 5 | 2 | HP:0010775 | |
| HumanPheno | Hepatic hemangioma | 4.62e-06 | 4 | 5 | 2 | HP:0031207 | |
| HumanPheno | Papillary cystadenoma of the epididymis | 7.70e-06 | 5 | 5 | 2 | HP:0009715 | |
| HumanPheno | Supernumerary cusp | 7.70e-06 | 5 | 5 | 2 | HP:0033777 | |
| HumanPheno | Epididymal neoplasm | 7.70e-06 | 5 | 5 | 2 | HP:0030421 | |
| HumanPheno | Large foramen magnum | 1.15e-05 | 6 | 5 | 2 | HP:0002700 | |
| HumanPheno | Panic attack | 1.17e-05 | 55 | 5 | 3 | HP:0025269 | |
| HumanPheno | Non-epileptic seizure | 1.24e-05 | 56 | 5 | 3 | HP:0033052 | |
| HumanPheno | Deviated nasal septum | 1.62e-05 | 7 | 5 | 2 | HP:0004411 | |
| HumanPheno | Pilomatrixoma | 2.77e-05 | 9 | 5 | 2 | HP:0030434 | |
| HumanPheno | Cervical cord compression | 2.77e-05 | 9 | 5 | 2 | HP:0002341 | |
| HumanPheno | Frontal hirsutism | 3.46e-05 | 10 | 5 | 2 | HP:0011335 | |
| HumanPheno | Abnormal subclavian artery morphology | 4.22e-05 | 11 | 5 | 2 | HP:0031251 | |
| HumanPheno | Facial grimacing | 5.99e-05 | 13 | 5 | 2 | HP:0000273 | |
| HumanPheno | Keloids | 5.99e-05 | 13 | 5 | 2 | HP:0010562 | |
| HumanPheno | Parietal foramina | 6.98e-05 | 14 | 5 | 2 | HP:0002697 | |
| HumanPheno | Duplication of phalanx of hallux | 6.98e-05 | 14 | 5 | 2 | HP:0010066 | |
| HumanPheno | Hypoplastic aortic arch | 6.98e-05 | 14 | 5 | 2 | HP:0012304 | |
| HumanPheno | Social and occupational deterioration | 8.05e-05 | 15 | 5 | 2 | HP:0007086 | |
| HumanPheno | Duplication of phalanx of toe | 8.05e-05 | 15 | 5 | 2 | HP:0010181 | |
| HumanPheno | Square face | 9.20e-05 | 16 | 5 | 2 | HP:0000321 | |
| HumanPheno | Premature thelarche | 1.04e-04 | 17 | 5 | 2 | HP:0010314 | |
| HumanPheno | Facial hirsutism | 1.17e-04 | 18 | 5 | 2 | HP:0009937 | |
| HumanPheno | Skin appendage neoplasm | 1.17e-04 | 18 | 5 | 2 | HP:0012842 | |
| HumanPheno | Absent earlobe | 1.45e-04 | 20 | 5 | 2 | HP:0000387 | |
| HumanPheno | Localized hirsutism | 1.61e-04 | 21 | 5 | 2 | HP:0009889 | |
| HumanPheno | Deep plantar creases | 1.61e-04 | 21 | 5 | 2 | HP:0001869 | |
| HumanPheno | Corneal scarring | 1.61e-04 | 21 | 5 | 2 | HP:0000559 | |
| HumanPheno | Abnormal foramen magnum morphology | 1.93e-04 | 23 | 5 | 2 | HP:0002699 | |
| HumanPheno | Agenesis of permanent teeth | 1.93e-04 | 23 | 5 | 2 | HP:0006349 | |
| HumanPheno | Simple ear | 2.11e-04 | 24 | 5 | 2 | HP:0020206 | |
| HumanPheno | Broad hallux phalanx | 2.11e-04 | 24 | 5 | 2 | HP:0010059 | |
| HumanPheno | Shawl scrotum | 2.29e-04 | 25 | 5 | 2 | HP:0000049 | |
| HumanPheno | Full cheeks | 2.44e-04 | 151 | 5 | 3 | HP:0000293 | |
| HumanPheno | Minor feet anomalies | 2.48e-04 | 26 | 5 | 2 | HP:0010613 | |
| HumanPheno | Abnormal feet morphology | 2.48e-04 | 26 | 5 | 2 | HP:0010611 | |
| HumanPheno | Phonophobia | 2.48e-04 | 26 | 5 | 2 | HP:0002183 | |
| HumanPheno | Perimembranous ventricular septal defect | 2.48e-04 | 26 | 5 | 2 | HP:0011682 | |
| HumanPheno | Flared iliac wing | 2.68e-04 | 27 | 5 | 2 | HP:0002869 | |
| HumanPheno | Broad distal phalanx of finger | 2.68e-04 | 27 | 5 | 2 | HP:0009836 | |
| HumanPheno | High, narrow palate | 2.69e-04 | 156 | 5 | 3 | HP:0002705 | |
| HumanPheno | Compulsive behaviors | 2.80e-04 | 158 | 5 | 3 | HP:0000722 | |
| HumanPheno | Short columella | 3.10e-04 | 29 | 5 | 2 | HP:0002000 | |
| HumanPheno | Abnormal parietal bone morphology | 3.10e-04 | 29 | 5 | 2 | HP:0002696 | |
| HumanPheno | Broad eyebrow | 3.10e-04 | 29 | 5 | 2 | HP:0011229 | |
| HumanPheno | Mood alterations | 3.12e-04 | 164 | 5 | 3 | HP:0001296 | |
| HumanPheno | Emotional lability | 3.12e-04 | 164 | 5 | 3 | HP:0000712 | |
| HumanPheno | Avascular necrosis of the capital femoral epiphysis | 3.32e-04 | 30 | 5 | 2 | HP:0005743 | |
| HumanPheno | Abnormal epididymis morphology | 3.32e-04 | 30 | 5 | 2 | HP:0009714 | |
| HumanPheno | Preaxial foot polydactyly | 3.32e-04 | 30 | 5 | 2 | HP:0001841 | |
| HumanPheno | Hypoplastic iliac wing | 3.54e-04 | 31 | 5 | 2 | HP:0002866 | |
| HumanPheno | Maladaptive fear-related cognitions | 3.70e-04 | 483 | 5 | 4 | HP:5200230 | |
| HumanPheno | Anxiety | 3.70e-04 | 483 | 5 | 4 | HP:0000739 | |
| HumanPheno | Frontal upsweep of hair | 4.02e-04 | 33 | 5 | 2 | HP:0002236 | |
| HumanPheno | Syringomyelia | 4.02e-04 | 33 | 5 | 2 | HP:0003396 | |
| HumanPheno | Abnormal branching pattern of the aortic arch | 4.02e-04 | 33 | 5 | 2 | HP:0011587 | |
| HumanPheno | Aspiration | 4.27e-04 | 34 | 5 | 2 | HP:0002835 | |
| HumanPheno | Abnormal number of permanent teeth | 4.53e-04 | 35 | 5 | 2 | HP:0011044 | |
| HumanPheno | Abnormal judgment | 4.79e-04 | 516 | 5 | 4 | HP:5200401 | |
| HumanPheno | Hydrocele testis | 4.79e-04 | 36 | 5 | 2 | HP:0000034 | |
| HumanPheno | Disturbance of facial expression | 4.79e-04 | 36 | 5 | 2 | HP:0005324 | |
| HumanPheno | Abnormality of the distal phalanx of the thumb | 4.79e-04 | 36 | 5 | 2 | HP:0009617 | |
| HumanPheno | Nasolacrimal duct obstruction | 4.79e-04 | 36 | 5 | 2 | HP:0000579 | |
| HumanPheno | Auditory sensitivity | 5.06e-04 | 37 | 5 | 2 | HP:0025112 | |
| HumanPheno | Accessory spleen | 5.06e-04 | 37 | 5 | 2 | HP:0001747 | |
| HumanPheno | Auditory hypersensitivity | 5.06e-04 | 37 | 5 | 2 | HP:5200060 | |
| HumanPheno | Nasogastric tube feeding in infancy | 5.06e-04 | 37 | 5 | 2 | HP:0011470 | |
| HumanPheno | Natal tooth | 5.34e-04 | 38 | 5 | 2 | HP:0000695 | |
| HumanPheno | Secondary microcephaly | 5.62e-04 | 200 | 5 | 3 | HP:0005484 | |
| HumanPheno | Capillary hemangioma | 5.63e-04 | 39 | 5 | 2 | HP:0005306 | |
| HumanPheno | Cellular immunodeficiency | 5.63e-04 | 39 | 5 | 2 | HP:0005374 | |
| HumanPheno | Poor coordination | 5.63e-04 | 39 | 5 | 2 | HP:0002370 | |
| HumanPheno | Abnormal fear-induced behavior | 5.64e-04 | 538 | 5 | 4 | HP:0100852 | |
| HumanPheno | Narrow palate | 5.79e-04 | 202 | 5 | 3 | HP:0000189 | |
| HumanPheno | Abnormal hair whorl | 6.53e-04 | 42 | 5 | 2 | HP:0010721 | |
| HumanPheno | Juvenile aseptic necrosis | 6.85e-04 | 43 | 5 | 2 | HP:0100323 | |
| HumanPheno | Meningioma | 7.17e-04 | 44 | 5 | 2 | HP:0002858 | |
| HumanPheno | Spinal cord compression | 7.17e-04 | 44 | 5 | 2 | HP:0002176 | |
| HumanPheno | Spinal cord lesion | 7.84e-04 | 46 | 5 | 2 | HP:0100561 | |
| HumanPheno | Abnormal hallux phalanx morphology | 7.84e-04 | 46 | 5 | 2 | HP:0010057 | |
| HumanPheno | Advanced eruption of teeth | 7.84e-04 | 46 | 5 | 2 | HP:0006288 | |
| HumanPheno | Prominent fingertip pads | 7.84e-04 | 46 | 5 | 2 | HP:0001212 | |
| HumanPheno | Broad phalanx of the toes | 8.19e-04 | 47 | 5 | 2 | HP:0010174 | |
| HumanPheno | Chiari type I malformation | 8.54e-04 | 48 | 5 | 2 | HP:0007099 | |
| HumanPheno | Prominent digit pad | 8.54e-04 | 48 | 5 | 2 | HP:0011298 | |
| HumanPheno | Hypoplastic left heart | 8.90e-04 | 49 | 5 | 2 | HP:0004383 | |
| HumanPheno | Cutaneous syndactyly of toes | 9.27e-04 | 50 | 5 | 2 | HP:0010621 | |
| MousePheno | thin ventricle myocardium compact layer | 1.06e-04 | 20 | 11 | 2 | MP:0010556 | |
| MousePheno | decreased circulating glucagon level | 1.06e-04 | 20 | 11 | 2 | MP:0002696 | |
| Domain | Nuc_rcpt_coact | 5.26e-09 | 6 | 13 | 3 | IPR009110 | |
| Domain | - | 4.47e-07 | 2 | 13 | 2 | 1.10.246.20 | |
| Domain | zf-TAZ | 4.47e-07 | 2 | 13 | 2 | PF02135 | |
| Domain | ZF_TAZ | 4.47e-07 | 2 | 13 | 2 | PS50134 | |
| Domain | - | 4.47e-07 | 2 | 13 | 2 | 1.20.1020.10 | |
| Domain | RING_CBP-p300 | 4.47e-07 | 2 | 13 | 2 | IPR010303 | |
| Domain | KAT11 | 4.47e-07 | 2 | 13 | 2 | SM01250 | |
| Domain | Nuc_rcpt_coact_CREBbp | 4.47e-07 | 2 | 13 | 2 | IPR014744 | |
| Domain | HAT_KAT11 | 4.47e-07 | 2 | 13 | 2 | PF08214 | |
| Domain | - | 4.47e-07 | 2 | 13 | 2 | 1.10.1630.10 | |
| Domain | KIX | 4.47e-07 | 2 | 13 | 2 | PS50952 | |
| Domain | Znf_TAZ | 4.47e-07 | 2 | 13 | 2 | IPR000197 | |
| Domain | KIX_dom | 4.47e-07 | 2 | 13 | 2 | IPR003101 | |
| Domain | Creb_binding | 4.47e-07 | 2 | 13 | 2 | PF09030 | |
| Domain | KIX | 4.47e-07 | 2 | 13 | 2 | PF02172 | |
| Domain | ZnF_TAZ | 4.47e-07 | 2 | 13 | 2 | SM00551 | |
| Domain | CBP_P300_HAT | 4.47e-07 | 2 | 13 | 2 | IPR031162 | |
| Domain | Histone_AcTrfase_Rtt109/CBP | 4.47e-07 | 2 | 13 | 2 | IPR013178 | |
| Domain | CBP_P300_HAT | 4.47e-07 | 2 | 13 | 2 | PS51727 | |
| Domain | DUF902 | 4.47e-07 | 2 | 13 | 2 | PF06001 | |
| Domain | BROMODOMAIN_1 | 2.02e-06 | 37 | 13 | 3 | PS00633 | |
| Domain | Bromodomain | 2.19e-06 | 38 | 13 | 3 | PF00439 | |
| Domain | BROMODOMAIN_2 | 2.77e-06 | 41 | 13 | 3 | PS50014 | |
| Domain | BROMO | 2.98e-06 | 42 | 13 | 3 | SM00297 | |
| Domain | Bromodomain | 2.98e-06 | 42 | 13 | 3 | IPR001487 | |
| Domain | - | 2.98e-06 | 42 | 13 | 3 | 1.20.920.10 | |
| Domain | ZF_ZZ_1 | 6.80e-05 | 18 | 13 | 2 | PS01357 | |
| Domain | ZF_ZZ_2 | 6.80e-05 | 18 | 13 | 2 | PS50135 | |
| Domain | ZZ | 6.80e-05 | 18 | 13 | 2 | PF00569 | |
| Domain | ZnF_ZZ | 7.60e-05 | 19 | 13 | 2 | SM00291 | |
| Domain | Znf_ZZ | 7.60e-05 | 19 | 13 | 2 | IPR000433 | |
| Domain | Bromodomain_CS | 1.44e-04 | 26 | 13 | 2 | IPR018359 | |
| Domain | - | 3.30e-03 | 449 | 13 | 3 | 3.30.40.10 | |
| Domain | Znf_RING/FYVE/PHD | 3.51e-03 | 459 | 13 | 3 | IPR013083 | |
| Domain | Znf_FYVE_PHD | 4.53e-03 | 147 | 13 | 2 | IPR011011 | |
| Domain | Znf_RING_CS | 5.54e-03 | 163 | 13 | 2 | IPR017907 | |
| Domain | ZF_RING_1 | 1.68e-02 | 291 | 13 | 2 | PS00518 | |
| Domain | ZF_RING_2 | 1.76e-02 | 298 | 13 | 2 | PS50089 | |
| Domain | RING | 1.84e-02 | 305 | 13 | 2 | SM00184 | |
| Domain | Znf_RING | 2.09e-02 | 326 | 13 | 2 | IPR001841 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 1.71e-07 | 14 | 12 | 3 | M27808 | |
| Pathway | REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS | 2.62e-07 | 16 | 12 | 3 | M27121 | |
| Pathway | REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 5.33e-07 | 20 | 12 | 3 | M27881 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 7.19e-07 | 22 | 12 | 3 | MM1370 | |
| Pathway | REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 1.07e-06 | 25 | 12 | 3 | M27880 | |
| Pathway | PID_RETINOIC_ACID_PATHWAY | 1.89e-06 | 30 | 12 | 3 | M207 | |
| Pathway | REACTOME_GASTRULATION | 3.13e-06 | 129 | 12 | 4 | M46433 | |
| Pathway | REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT | 5.31e-06 | 42 | 12 | 3 | M17541 | |
| Pathway | PID_HNF3A_PATHWAY | 6.12e-06 | 44 | 12 | 3 | M285 | |
| Pathway | BIOCARTA_PELP1_PATHWAY | 6.63e-06 | 5 | 12 | 2 | MM1575 | |
| Pathway | REACTOME_NFE2L2_REGULATING_INFLAMMATION_ASSOCIATED_GENES | 6.63e-06 | 5 | 12 | 2 | M48020 | |
| Pathway | REACTOME_LRR_FLII_INTERACTING_PROTEIN_1_LRRFIP1_ACTIVATES_TYPE_I_IFN_PRODUCTION | 6.63e-06 | 5 | 12 | 2 | M27228 | |
| Pathway | REACTOME_NFE2L2_REGULATING_ER_STRESS_ASSOCIATED_GENES | 6.63e-06 | 5 | 12 | 2 | M48023 | |
| Pathway | KEGG_NOTCH_SIGNALING_PATHWAY | 7.48e-06 | 47 | 12 | 3 | M7946 | |
| Pathway | REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 7.98e-06 | 48 | 12 | 3 | M611 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH3 | 8.49e-06 | 49 | 12 | 3 | M618 | |
| Pathway | BIOCARTA_PELP1_PATHWAY | 9.95e-06 | 6 | 12 | 2 | M22062 | |
| Pathway | BIOCARTA_PPARG_PATHWAY | 1.39e-05 | 7 | 12 | 2 | MM1573 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1_PEST_DOMAIN_MUTANTS_IN_CANCER | 1.42e-05 | 58 | 12 | 3 | M29616 | |
| Pathway | BIOCARTA_PPARG_PATHWAY | 1.85e-05 | 8 | 12 | 2 | M22058 | |
| Pathway | REACTOME_NFE2L2_REGULATING_MDR_ASSOCIATED_ENZYMES | 1.85e-05 | 8 | 12 | 2 | M48022 | |
| Pathway | REACTOME_REGULATION_OF_NFE2L2_GENE_EXPRESSION | 1.85e-05 | 8 | 12 | 2 | M48024 | |
| Pathway | REACTOME_NFE2L2_REGULATES_PENTOSE_PHOSPHATE_PATHWAY_GENES | 1.85e-05 | 8 | 12 | 2 | M46443 | |
| Pathway | WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA | 2.00e-05 | 65 | 12 | 3 | M39682 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TLR3_IRF3_SIGNALING_PATHWAY | 2.38e-05 | 9 | 12 | 2 | M47451 | |
| Pathway | REACTOME_FORMATION_OF_PARAXIAL_MESODERM | 2.39e-05 | 69 | 12 | 3 | M46439 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1 | 2.95e-05 | 74 | 12 | 3 | M616 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 2.98e-05 | 10 | 12 | 2 | MM15535 | |
| Pathway | REACTOME_REGULATION_OF_FOXO_TRANSCRIPTIONAL_ACTIVITY_BY_ACETYLATION | 2.98e-05 | 10 | 12 | 2 | M27945 | |
| Pathway | BIOCARTA_CARM1_PATHWAY | 3.64e-05 | 11 | 12 | 2 | MM1521 | |
| Pathway | REACTOME_NFE2L2_REGULATING_TUMORIGENIC_GENES | 3.64e-05 | 11 | 12 | 2 | M48021 | |
| Pathway | REACTOME_REGULATION_OF_GENE_EXPRESSION_BY_HYPOXIA_INDUCIBLE_FACTOR | 3.64e-05 | 11 | 12 | 2 | M26924 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH4 | 4.02e-05 | 82 | 12 | 3 | M594 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION | 4.32e-05 | 84 | 12 | 3 | M1008 | |
| Pathway | BIOCARTA_CARM1_PATHWAY | 4.36e-05 | 12 | 12 | 2 | M7968 | |
| Pathway | REACTOME_ACTIVATION_OF_THE_TFAP2_AP_2_FAMILY_OF_TRANSCRIPTION_FACTORS | 4.36e-05 | 12 | 12 | 2 | M27765 | |
| Pathway | REACTOME_NOTCH2_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 4.36e-05 | 12 | 12 | 2 | M27159 | |
| Pathway | WP_ANDROGEN_RECEPTOR_SIGNALING | 5.49e-05 | 91 | 12 | 3 | M39700 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3 | 6.44e-05 | 96 | 12 | 3 | M27784 | |
| Pathway | BIOCARTA_RELA_PATHWAY | 6.93e-05 | 15 | 12 | 2 | MM1339 | |
| Pathway | BIOCARTA_RELA_PATHWAY | 6.93e-05 | 15 | 12 | 2 | M10183 | |
| Pathway | BIOCARTA_PITX2_PATHWAY | 6.93e-05 | 15 | 12 | 2 | MM1439 | |
| Pathway | WP_RUBINSTEINTAYBI_SYNDROME_1 | 6.93e-05 | 15 | 12 | 2 | M48323 | |
| Pathway | REACTOME_TRAF3_DEPENDENT_IRF_ACTIVATION_PATHWAY | 6.93e-05 | 15 | 12 | 2 | M953 | |
| Pathway | BIOCARTA_IL7_PATHWAY | 7.92e-05 | 16 | 12 | 2 | M1296 | |
| Pathway | BIOCARTA_IL7_PATHWAY | 7.92e-05 | 16 | 12 | 2 | MM1420 | |
| Pathway | BIOCARTA_PITX2_PATHWAY | 7.92e-05 | 16 | 12 | 2 | M8516 | |
| Pathway | REACTOME_FOXO_MEDIATED_TRANSCRIPTION_OF_CELL_DEATH_GENES | 7.92e-05 | 16 | 12 | 2 | M27940 | |
| Pathway | WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY | 8.81e-05 | 301 | 12 | 4 | MM15983 | |
| Pathway | BIOCARTA_TGFB_PATHWAY | 8.97e-05 | 17 | 12 | 2 | MM1509 | |
| Pathway | REACTOME_ZYGOTIC_GENOME_ACTIVATION_ZGA | 8.97e-05 | 17 | 12 | 2 | M48025 | |
| Pathway | REACTOME_ADIPOGENESIS | 9.66e-05 | 110 | 12 | 3 | M48259 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1 | 1.01e-04 | 18 | 12 | 2 | MM14775 | |
| Pathway | REACTOME_RORA_ACTIVATES_GENE_EXPRESSION | 1.01e-04 | 18 | 12 | 2 | M26942 | |
| Pathway | BIOCARTA_TGFB_PATHWAY | 1.13e-04 | 19 | 12 | 2 | M18933 | |
| Pathway | REACTOME_NFE2L2_REGULATING_ANTI_OXIDANT_DETOXIFICATION_ENZYMES | 1.13e-04 | 19 | 12 | 2 | M46442 | |
| Pathway | REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA | 1.19e-04 | 118 | 12 | 3 | M27316 | |
| Pathway | REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING | 1.22e-04 | 119 | 12 | 3 | M607 | |
| Pathway | REACTOME_ACTIVATION_OF_ANTERIOR_HOX_GENES_IN_HINDBRAIN_DEVELOPMENT_DURING_EARLY_EMBRYOGENESIS | 1.31e-04 | 122 | 12 | 3 | M29689 | |
| Pathway | WP_HEMATOPOIETIC_STEM_CELL_GENE_REGULATION_BY_GABP_ALPHABETA_COMPLEX | 1.38e-04 | 21 | 12 | 2 | M39593 | |
| Pathway | REACTOME_CD209_DC_SIGN_SIGNALING | 1.38e-04 | 21 | 12 | 2 | M27485 | |
| Pathway | BIOCARTA_NTHI_PATHWAY | 1.52e-04 | 22 | 12 | 2 | MM1443 | |
| Pathway | BIOCARTA_NTHI_PATHWAY | 1.66e-04 | 23 | 12 | 2 | M2821 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 1.81e-04 | 24 | 12 | 2 | M13404 | |
| Pathway | BIOCARTA_CARM_ER_PATHWAY | 2.13e-04 | 26 | 12 | 2 | M2499 | |
| Pathway | PID_HDAC_CLASSIII_PATHWAY | 2.13e-04 | 26 | 12 | 2 | M32 | |
| Pathway | REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION | 2.37e-04 | 149 | 12 | 3 | M27888 | |
| Pathway | REACTOME_ATTENUATION_PHASE | 2.48e-04 | 28 | 12 | 2 | M27254 | |
| Pathway | REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY | 2.48e-04 | 28 | 12 | 2 | M6177 | |
| Pathway | REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION | 2.85e-04 | 30 | 12 | 2 | M936 | |
| Pathway | WP_INITIATION_OF_TRANSCRIPTION_AND_TRANSLATION_ELONGATION_AT_THE_HIV1_LTR | 3.25e-04 | 32 | 12 | 2 | M39521 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH2 | 3.46e-04 | 33 | 12 | 2 | M604 | |
| Pathway | WP_TYPE_2_PAPILLARY_RENAL_CELL_CARCINOMA | 3.67e-04 | 34 | 12 | 2 | M39771 | |
| Pathway | PID_HIF2PATHWAY | 3.67e-04 | 34 | 12 | 2 | M44 | |
| Pathway | REACTOME_EVASION_BY_RSV_OF_HOST_INTERFERON_RESPONSES | 3.89e-04 | 35 | 12 | 2 | M48246 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_THE_AP_2_TFAP2_FAMILY_OF_TRANSCRIPTION_FACTORS | 4.59e-04 | 38 | 12 | 2 | M27757 | |
| Pathway | REACTOME_HSF1_DEPENDENT_TRANSACTIVATION | 4.59e-04 | 38 | 12 | 2 | M27255 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH | 4.84e-04 | 39 | 12 | 2 | MM14604 | |
| Pathway | PID_FOXM1_PATHWAY | 5.09e-04 | 40 | 12 | 2 | M176 | |
| Pathway | PID_IFNG_PATHWAY | 5.09e-04 | 40 | 12 | 2 | M161 | |
| Pathway | REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS | 6.16e-04 | 44 | 12 | 2 | M27295 | |
| Pathway | WP_NOTCH_SIGNALING_WP268 | 6.44e-04 | 45 | 12 | 2 | M39571 | |
| Pathway | WP_NOTCH_SIGNALING_PATHWAY | 6.73e-04 | 46 | 12 | 2 | MM15971 | |
| Pathway | PID_HES_HEY_PATHWAY | 7.33e-04 | 48 | 12 | 2 | M288 | |
| Pathway | REACTOME_ESR_MEDIATED_SIGNALING | 7.43e-04 | 220 | 12 | 3 | M27794 | |
| Pathway | PID_FOXO_PATHWAY | 7.64e-04 | 49 | 12 | 2 | M136 | |
| Pathway | REACTOME_HEME_SIGNALING | 7.64e-04 | 49 | 12 | 2 | M41832 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_ACTIVITY_OF_SMAD2_SMAD3_SMAD4_HETEROTRIMER | 8.28e-04 | 51 | 12 | 2 | M665 | |
| Pathway | BIOCARTA_PPARA_PATHWAY | 8.60e-04 | 52 | 12 | 2 | M2404 | |
| Pathway | PID_NFAT_3PATHWAY | 8.94e-04 | 53 | 12 | 2 | M113 | |
| Pathway | PID_AR_TF_PATHWAY | 8.94e-04 | 53 | 12 | 2 | M151 | |
| Pathway | WP_TGFBETA_SIGNALING_PATHWAY | 8.94e-04 | 53 | 12 | 2 | MM15880 | |
| Pathway | WP_TGFBETA_RECEPTOR_SIGNALING | 9.62e-04 | 55 | 12 | 2 | M39351 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH | 1.03e-03 | 246 | 12 | 3 | M10189 | |
| Pathway | WP_TGFBETA_RECEPTOR_SIGNALING_IN_SKELETAL_DYSPLASIAS | 1.11e-03 | 59 | 12 | 2 | M39886 | |
| Pathway | PID_P53_REGULATION_PATHWAY | 1.11e-03 | 59 | 12 | 2 | M261 | |
| Pathway | WP_NOTCH_SIGNALING_WP61 | 1.18e-03 | 61 | 12 | 2 | M39540 | |
| Pathway | PID_ERA_GENOMIC_PATHWAY | 1.30e-03 | 64 | 12 | 2 | M200 | |
| Pathway | REACTOME_CYTOSOLIC_SENSORS_OF_PATHOGEN_ASSOCIATED_DNA | 1.30e-03 | 64 | 12 | 2 | M27046 | |
| Pathway | PID_RB_1PATHWAY | 1.34e-03 | 65 | 12 | 2 | M279 | |
| Pubmed | Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. | 4.08e-11 | 3 | 13 | 3 | 11823864 | |
| Pubmed | 4.08e-11 | 3 | 13 | 3 | 11349124 | ||
| Pubmed | CBP/p300 interact with and function as transcriptional coactivators of BRCA1. | 1.63e-10 | 4 | 13 | 3 | 10655477 | |
| Pubmed | 1.63e-10 | 4 | 13 | 3 | 16227615 | ||
| Pubmed | 1.63e-10 | 4 | 13 | 3 | 33589584 | ||
| Pubmed | 1.63e-10 | 4 | 13 | 3 | 11701890 | ||
| Pubmed | Temporal/spatial expression of nuclear receptor coactivators in the mouse lung. | 8.15e-10 | 6 | 13 | 3 | 11076796 | |
| Pubmed | 2.28e-09 | 8 | 13 | 3 | 17475621 | ||
| Pubmed | 2.28e-09 | 8 | 13 | 3 | 10490106 | ||
| Pubmed | Identification and functional characterization of transcriptional activators in human cells. | 3.47e-09 | 398 | 13 | 6 | 35016035 | |
| Pubmed | Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. | 4.89e-09 | 10 | 13 | 3 | 16751102 | |
| Pubmed | 4.89e-09 | 10 | 13 | 3 | 11163245 | ||
| Pubmed | 6.72e-09 | 11 | 13 | 3 | 18003620 | ||
| Pubmed | 8.53e-09 | 1429 | 13 | 8 | 35140242 | ||
| Pubmed | Histone acetyltransferase-dependent chromatin remodeling and the vascular clock. | 8.96e-09 | 12 | 13 | 3 | 14645221 | |
| Pubmed | 1.85e-08 | 15 | 13 | 3 | 9267036 | ||
| Pubmed | 2.77e-08 | 17 | 13 | 3 | 19183483 | ||
| Pubmed | 3.20e-08 | 268 | 13 | 5 | 33640491 | ||
| Pubmed | 4.60e-08 | 1103 | 13 | 7 | 34189442 | ||
| Pubmed | 4.63e-08 | 20 | 13 | 3 | 11877444 | ||
| Pubmed | 5.40e-08 | 21 | 13 | 3 | 19596656 | ||
| Pubmed | Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. | 7.38e-08 | 113 | 13 | 4 | 23403292 | |
| Pubmed | Interaction network of human early embryonic transcription factors. | 1.23e-07 | 351 | 13 | 5 | 38297188 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 27881875 | ||
| Pubmed | Expression of the nuclear coactivators CBP and p300 in developing craniofacial tissue. | 1.29e-07 | 2 | 13 | 2 | 11963968 | |
| Pubmed | Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. | 1.29e-07 | 2 | 13 | 2 | 34845315 | |
| Pubmed | p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes. | 1.29e-07 | 2 | 13 | 2 | 34813504 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 19729597 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 15860545 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 9528808 | ||
| Pubmed | Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines. | 1.29e-07 | 2 | 13 | 2 | 12696060 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 29460469 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 28675294 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 20301699 | ||
| Pubmed | Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer. | 1.29e-07 | 2 | 13 | 2 | 24551300 | |
| Pubmed | CBP Is Required for Establishing Adaptive Gene Programs in the Adult Mouse Brain. | 1.29e-07 | 2 | 13 | 2 | 36109165 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 24639469 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 37816914 | ||
| Pubmed | Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin. | 1.29e-07 | 2 | 13 | 2 | 21632823 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 12242694 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 33911074 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 9018065 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 24648406 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 30135524 | ||
| Pubmed | Binding of p300/CBP co-activators by polyoma large T antigen. | 1.29e-07 | 2 | 13 | 2 | 11438528 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 10918613 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 31182547 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 35502657 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 39287984 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 30635043 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 31898871 | ||
| Pubmed | Distribution of co-activators CBP and p300 during mouse oocyte and embryo development. | 1.29e-07 | 2 | 13 | 2 | 16596650 | |
| Pubmed | Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations. | 1.29e-07 | 2 | 13 | 2 | 27648933 | |
| Pubmed | Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity. | 1.29e-07 | 2 | 13 | 2 | 30888860 | |
| Pubmed | Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. | 1.29e-07 | 2 | 13 | 2 | 27881443 | |
| Pubmed | The p300 and CBP Transcriptional Coactivators Are Required for β-Cell and α-Cell Proliferation. | 1.29e-07 | 2 | 13 | 2 | 29217654 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 19272189 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 10610021 | ||
| Pubmed | Emerging roles of p300/CBP in autophagy and autophagy-related human disorders. | 1.29e-07 | 2 | 13 | 2 | 37314181 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 20717166 | ||
| Pubmed | Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. | 1.29e-07 | 2 | 13 | 2 | 12397173 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 10049825 | ||
| Pubmed | CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding. | 1.29e-07 | 2 | 13 | 2 | 15641773 | |
| Pubmed | Differential contribution of p300 and CBP to regulatory element acetylation in mESCs. | 1.29e-07 | 2 | 13 | 2 | 32690000 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 9733868 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 30953353 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 21803292 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 9811832 | ||
| Pubmed | CBP/p300 acetyltransferase activity in hematologic malignancies. | 1.29e-07 | 2 | 13 | 2 | 27380996 | |
| Pubmed | CREBBP and p300 lysine acetyl transferases in the DNA damage response. | 1.29e-07 | 2 | 13 | 2 | 29170789 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 24089570 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 25893291 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 11559821 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 21555743 | ||
| Pubmed | Rubinstein-Taybi syndrome in Chinese population with four novel mutations. | 1.29e-07 | 2 | 13 | 2 | 33063428 | |
| Pubmed | CBP/p300 induction is required for retinoic acid sensitivity in human mammary cells. | 1.29e-07 | 2 | 13 | 2 | 12646247 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 34506759 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 22177454 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 15706485 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 32576962 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 19822209 | ||
| Pubmed | AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. | 1.29e-07 | 2 | 13 | 2 | 39266679 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 24522976 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 22303793 | ||
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 11867645 | ||
| Pubmed | CBP is required for environmental enrichment-induced neurogenesis and cognitive enhancement. | 1.29e-07 | 2 | 13 | 2 | 21847097 | |
| Pubmed | 1.29e-07 | 2 | 13 | 2 | 34732714 | ||
| Pubmed | Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. | 1.29e-07 | 2 | 13 | 2 | 34019788 | |
| Pubmed | 1.33e-07 | 28 | 13 | 3 | 24880616 | ||
| Pubmed | 2.23e-07 | 396 | 13 | 5 | 26687479 | ||
| Pubmed | 3.16e-07 | 425 | 13 | 5 | 24999758 | ||
| Pubmed | 3.87e-07 | 3 | 13 | 2 | 15598887 | ||
| Pubmed | Dendrite development regulated by CREST, a calcium-regulated transcriptional activator. | 3.87e-07 | 3 | 13 | 2 | 14716005 | |
| Pubmed | The acetate/ACSS2 switch regulates HIF-2 stress signaling in the tumor cell microenvironment. | 3.87e-07 | 3 | 13 | 2 | 25689462 | |
| Pubmed | 3.87e-07 | 3 | 13 | 2 | 18070920 | ||
| Pubmed | 3.87e-07 | 3 | 13 | 2 | 11973335 | ||
| Pubmed | The acetylation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression. | 3.87e-07 | 3 | 13 | 2 | 21967847 | |
| Pubmed | 3.87e-07 | 3 | 13 | 2 | 9194564 | ||
| Pubmed | 3.87e-07 | 3 | 13 | 2 | 15171256 | ||
| Pubmed | p300/CBP acts as a coactivator of the cone-rod homeobox transcription factor. | 3.87e-07 | 3 | 13 | 2 | 10708567 | |
| Interaction | SOX7 interactions | 1.24e-09 | 82 | 13 | 5 | int:SOX7 | |
| Interaction | SP7 interactions | 1.76e-08 | 304 | 13 | 6 | int:SP7 | |
| Interaction | EGR2 interactions | 5.05e-08 | 171 | 13 | 5 | int:EGR2 | |
| Interaction | MYOD1 interactions | 9.49e-08 | 194 | 13 | 5 | int:MYOD1 | |
| Interaction | FOXI1 interactions | 2.82e-07 | 92 | 13 | 4 | int:FOXI1 | |
| Interaction | SOX9 interactions | 3.49e-07 | 97 | 13 | 4 | int:SOX9 | |
| Interaction | CRX interactions | 3.62e-07 | 254 | 13 | 5 | int:CRX | |
| Interaction | EWSR1 interactions | 4.91e-07 | 906 | 13 | 7 | int:EWSR1 | |
| Interaction | HNF4A interactions | 5.37e-07 | 275 | 13 | 5 | int:HNF4A | |
| Interaction | AR interactions | 9.06e-07 | 992 | 13 | 7 | int:AR | |
| Interaction | FOS interactions | 1.00e-06 | 312 | 13 | 5 | int:FOS | |
| Interaction | TRERF1 interactions | 1.13e-06 | 33 | 13 | 3 | int:TRERF1 | |
| Interaction | HOXB2 interactions | 1.48e-06 | 36 | 13 | 3 | int:HOXB2 | |
| Interaction | TCF12 interactions | 1.90e-06 | 148 | 13 | 4 | int:TCF12 | |
| Interaction | TFF1 interactions | 2.20e-06 | 41 | 13 | 3 | int:TFF1 | |
| Interaction | NPAS2 interactions | 2.37e-06 | 42 | 13 | 3 | int:NPAS2 | |
| Interaction | TLX1 interactions | 3.70e-06 | 175 | 13 | 4 | int:TLX1 | |
| Interaction | CEBPA interactions | 4.17e-06 | 1245 | 13 | 7 | int:CEBPA | |
| Interaction | EID1 interactions | 4.29e-06 | 51 | 13 | 3 | int:EID1 | |
| Interaction | CCNA2 interactions | 4.41e-06 | 183 | 13 | 4 | int:CCNA2 | |
| Interaction | NUP35 interactions | 4.51e-06 | 424 | 13 | 5 | int:NUP35 | |
| Interaction | GATA3 interactions | 4.81e-06 | 187 | 13 | 4 | int:GATA3 | |
| Interaction | NFIA interactions | 4.91e-06 | 188 | 13 | 4 | int:NFIA | |
| Interaction | HNF1B interactions | 5.12e-06 | 190 | 13 | 4 | int:HNF1B | |
| Interaction | KLF5 interactions | 5.68e-06 | 195 | 13 | 4 | int:KLF5 | |
| Interaction | GATA2 interactions | 6.15e-06 | 199 | 13 | 4 | int:GATA2 | |
| Interaction | ETS2 interactions | 7.39e-06 | 61 | 13 | 3 | int:ETS2 | |
| Interaction | JUN interactions | 7.45e-06 | 470 | 13 | 5 | int:JUN | |
| Interaction | NFIC interactions | 7.61e-06 | 210 | 13 | 4 | int:NFIC | |
| Interaction | CEBPD interactions | 7.76e-06 | 62 | 13 | 3 | int:CEBPD | |
| Interaction | NANOG interactions | 8.33e-06 | 481 | 13 | 5 | int:NANOG | |
| Interaction | ERG interactions | 9.65e-06 | 223 | 13 | 4 | int:ERG | |
| Interaction | SPI1 interactions | 9.81e-06 | 67 | 13 | 3 | int:SPI1 | |
| Interaction | NCOA3 interactions | 9.82e-06 | 224 | 13 | 4 | int:NCOA3 | |
| Interaction | GCM1 interactions | 1.03e-05 | 68 | 13 | 3 | int:GCM1 | |
| Interaction | ETV4 interactions | 1.07e-05 | 69 | 13 | 3 | int:ETV4 | |
| Interaction | MAML1 interactions | 1.27e-05 | 73 | 13 | 3 | int:MAML1 | |
| Interaction | EYA4 interactions | 1.35e-05 | 243 | 13 | 4 | int:EYA4 | |
| Interaction | HOXB3 interactions | 1.38e-05 | 9 | 13 | 2 | int:HOXB3 | |
| Interaction | ARGFX interactions | 1.38e-05 | 9 | 13 | 2 | int:ARGFX | |
| Interaction | TBP interactions | 1.59e-05 | 253 | 13 | 4 | int:TBP | |
| Interaction | RBPJ interactions | 1.61e-05 | 254 | 13 | 4 | int:RBPJ | |
| Interaction | HNF1A interactions | 1.67e-05 | 80 | 13 | 3 | int:HNF1A | |
| Interaction | STAT6 interactions | 2.15e-05 | 87 | 13 | 3 | int:STAT6 | |
| Interaction | GSC interactions | 2.15e-05 | 87 | 13 | 3 | int:GSC | |
| Interaction | CREBBP interactions | 2.41e-05 | 599 | 13 | 5 | int:CREBBP | |
| Interaction | FDCSP interactions | 2.53e-05 | 12 | 13 | 2 | int:FDCSP | |
| Interaction | TAL1 interactions | 2.63e-05 | 93 | 13 | 3 | int:TAL1 | |
| Interaction | SOX17 interactions | 2.80e-05 | 95 | 13 | 3 | int:SOX17 | |
| Interaction | CSE1L interactions | 3.70e-05 | 314 | 13 | 4 | int:CSE1L | |
| Interaction | KLF2 interactions | 4.01e-05 | 15 | 13 | 2 | int:KLF2 | |
| Interaction | PCAT1 interactions | 4.01e-05 | 15 | 13 | 2 | int:PCAT1 | |
| Interaction | KLF8 interactions | 4.44e-05 | 329 | 13 | 4 | int:KLF8 | |
| Interaction | PAX8 interactions | 4.47e-05 | 111 | 13 | 3 | int:PAX8 | |
| Interaction | THRA interactions | 4.47e-05 | 111 | 13 | 3 | int:THRA | |
| Interaction | TBXT interactions | 5.10e-05 | 116 | 13 | 3 | int:TBXT | |
| Interaction | KISS1 interactions | 5.20e-05 | 17 | 13 | 2 | int:KISS1 | |
| Interaction | MAML2 interactions | 5.20e-05 | 17 | 13 | 2 | int:MAML2 | |
| Interaction | DDIT3 interactions | 5.64e-05 | 120 | 13 | 3 | int:DDIT3 | |
| Interaction | ETS1 interactions | 5.78e-05 | 121 | 13 | 3 | int:ETS1 | |
| Interaction | SMARCC2 interactions | 5.84e-05 | 353 | 13 | 4 | int:SMARCC2 | |
| Interaction | KAT5 interactions | 6.17e-05 | 358 | 13 | 4 | int:KAT5 | |
| Interaction | PAX7 interactions | 6.22e-05 | 124 | 13 | 3 | int:PAX7 | |
| Interaction | NCOR1 interactions | 6.51e-05 | 363 | 13 | 4 | int:NCOR1 | |
| Interaction | NEUROG1 interactions | 6.53e-05 | 19 | 13 | 2 | int:NEUROG1 | |
| Interaction | VDR interactions | 6.67e-05 | 127 | 13 | 3 | int:VDR | |
| Interaction | PAX6 interactions | 6.72e-05 | 366 | 13 | 4 | int:PAX6 | |
| Interaction | DDA1 interactions | 6.86e-05 | 368 | 13 | 4 | int:DDA1 | |
| Interaction | RAD50 interactions | 7.08e-05 | 371 | 13 | 4 | int:RAD50 | |
| Interaction | MYH9 interactions | 7.25e-05 | 754 | 13 | 5 | int:MYH9 | |
| Interaction | SPIB interactions | 7.25e-05 | 20 | 13 | 2 | int:SPIB | |
| Interaction | FUS interactions | 7.39e-05 | 757 | 13 | 5 | int:FUS | |
| Interaction | TLE3 interactions | 7.46e-05 | 376 | 13 | 4 | int:TLE3 | |
| Interaction | MYB interactions | 7.66e-05 | 133 | 13 | 3 | int:MYB | |
| Interaction | CITED4 interactions | 8.01e-05 | 21 | 13 | 2 | int:CITED4 | |
| Interaction | HOXB4 interactions | 8.01e-05 | 21 | 13 | 2 | int:HOXB4 | |
| Interaction | PLAGL1 interactions | 8.01e-05 | 21 | 13 | 2 | int:PLAGL1 | |
| Interaction | KLF13 interactions | 8.01e-05 | 21 | 13 | 2 | int:KLF13 | |
| Interaction | SMARCC1 interactions | 8.10e-05 | 384 | 13 | 4 | int:SMARCC1 | |
| Interaction | SMAD2 interactions | 8.18e-05 | 385 | 13 | 4 | int:SMAD2 | |
| Interaction | ANAPC5 interactions | 8.54e-05 | 138 | 13 | 3 | int:ANAPC5 | |
| Interaction | NCOA2 interactions | 9.11e-05 | 141 | 13 | 3 | int:NCOA2 | |
| Interaction | GTF2B interactions | 9.11e-05 | 141 | 13 | 3 | int:GTF2B | |
| Interaction | NFIB interactions | 9.30e-05 | 142 | 13 | 3 | int:NFIB | |
| Interaction | PSME3 interactions | 9.30e-05 | 398 | 13 | 4 | int:PSME3 | |
| Interaction | CITED2 interactions | 9.64e-05 | 23 | 13 | 2 | int:CITED2 | |
| Interaction | HOXD10 interactions | 9.64e-05 | 23 | 13 | 2 | int:HOXD10 | |
| Interaction | NCOA1 interactions | 1.01e-04 | 146 | 13 | 3 | int:NCOA1 | |
| Interaction | SUPT5H interactions | 1.02e-04 | 408 | 13 | 4 | int:SUPT5H | |
| Interaction | TBX21 interactions | 1.05e-04 | 24 | 13 | 2 | int:TBX21 | |
| Interaction | CNTN2 interactions | 1.05e-04 | 24 | 13 | 2 | int:CNTN2 | |
| Interaction | NR6A1 interactions | 1.05e-04 | 24 | 13 | 2 | int:NR6A1 | |
| Interaction | MDC1 interactions | 1.08e-04 | 414 | 13 | 4 | int:MDC1 | |
| Interaction | ANXA2 interactions | 1.13e-04 | 419 | 13 | 4 | int:ANXA2 | |
| Interaction | H4C16 interactions | 1.14e-04 | 152 | 13 | 3 | int:H4C16 | |
| Interaction | TLE6 interactions | 1.14e-04 | 25 | 13 | 2 | int:TLE6 | |
| Interaction | ALX1 interactions | 1.14e-04 | 25 | 13 | 2 | int:ALX1 | |
| Interaction | WWTR1 interactions | 1.17e-04 | 422 | 13 | 4 | int:WWTR1 | |
| Interaction | USP9X interactions | 1.17e-04 | 422 | 13 | 4 | int:USP9X | |
| Interaction | HOXB7 interactions | 1.24e-04 | 26 | 13 | 2 | int:HOXB7 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr7q21 | 1.13e-03 | 178 | 13 | 2 | chr7q21 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 8.25e-08 | 17 | 10 | 3 | 486 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 4.19e-05 | 18 | 10 | 2 | 91 | |
| GeneFamily | Ataxins|Trinucleotide repeat containing | 8.20e-05 | 25 | 10 | 2 | 775 | |
| GeneFamily | Ring finger proteins | 9.57e-03 | 275 | 10 | 2 | 58 | |
| Coexpression | BUSSLINGER_GASTRIC_IMMUNE_CELLS | 1.08e-07 | 1492 | 13 | 8 | M40023 | |
| Coexpression | GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP | 1.47e-06 | 180 | 13 | 4 | M8239 | |
| Coexpression | GRESHOCK_CANCER_COPY_NUMBER_UP | 1.48e-05 | 323 | 13 | 4 | M9150 | |
| Coexpression | BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP | 3.13e-05 | 822 | 13 | 5 | M6782 | |
| Coexpression | GSE41867_NAIVE_VS_DAY15_LCMV_EFFECTOR_CD8_TCELL_DN | 1.18e-04 | 200 | 13 | 3 | M9472 | |
| Coexpression | FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP | 1.34e-04 | 568 | 13 | 4 | M4023 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Mandibular Arch_top-relative-expression-ranked_2500_k-means-cluster#5 | 3.65e-05 | 688 | 13 | 5 | Facebase_RNAseq_e10.5_Mandibular Arch_2500_K5 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_500 | 8.77e-05 | 413 | 13 | 4 | gudmap_developingGonad_e14.5_ epididymis_500 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_epididymis_emap-29702_k-means-cluster#2_top-relative-expression-ranked_500 | 1.18e-04 | 162 | 13 | 3 | gudmap_developingGonad_e16.5_epididymis_500_k2 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Lateral Nasal Eminence_top-relative-expression-ranked_500_k-means-cluster#4 | 1.95e-04 | 192 | 13 | 3 | Facebase_RNAseq_e10.5_Lateral Nasal Eminence_500_K4 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Flanking Eminence_top-relative-expression-ranked_1000 | 2.04e-04 | 989 | 13 | 5 | Facebase_RNAseq_e10.5_Neural Epithelium Flanking Eminence_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Hind Brain Neural Epithelium_top-relative-expression-ranked_2500_k-means-cluster#3 | 2.33e-04 | 532 | 13 | 4 | Facebase_RNAseq_e8.5_Hind Brain Neural Epithelium_2500_K3 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Hind Brain Neural Epithelium_top-relative-expression-ranked_1000_k-means-cluster#5 | 2.33e-04 | 204 | 13 | 3 | Facebase_RNAseq_e8.5_Hind Brain Neural Epithelium_1000_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_2500_k-means-cluster#4 | 3.57e-04 | 595 | 13 | 4 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_2500_K4 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Medial Nasal Eminence_top-relative-expression-ranked_2500_k-means-cluster#1 | 4.02e-04 | 614 | 13 | 4 | Facebase_RNAseq_e10.5_Medial Nasal Eminence_2500_K1 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_2500_k-means-cluster#5 | 4.41e-04 | 629 | 13 | 4 | Facebase_RNAseq_e10.5_Maxillary Arch_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#5 | 5.23e-04 | 658 | 13 | 4 | Facebase_RNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_2500_K5 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#3_top-relative-expression-ranked_1000 | 5.58e-04 | 275 | 13 | 3 | gudmap_developingGonad_e14.5_ epididymis_1000_k3 | |
| CoexpressionAtlas | DevelopingGonad_e12.5_ovary_emap-28876_k-means-cluster#3_top-relative-expression-ranked_1000 | 5.70e-04 | 277 | 13 | 3 | gudmap_developingGonad_e12.5_ovary_k3_1000 | |
| CoexpressionAtlas | facebase_RNAseq_e10.5_MandArch_2500_K1 | 5.86e-04 | 1241 | 13 | 5 | facebase_RNAseq_e10.5_MandArch_2500_K1 | |
| CoexpressionAtlas | DevelopingGonad_e18.5_epididymis_emap-13166_k-means-cluster#3_top-relative-expression-ranked_1000 | 5.94e-04 | 281 | 13 | 3 | gudmap_developingGonad_e18.5_epididymis_1000_k3 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Olfactory Placode_top-relative-expression-ranked_2500_k-means-cluster#4 | 6.02e-04 | 683 | 13 | 4 | Facebase_RNAseq_e9.5_Olfactory Placode_2500_K4 | |
| CoexpressionAtlas | facebase_RNAseq_e10.5_Emin_LatNas_2500_K3 | 6.22e-04 | 1257 | 13 | 5 | facebase_RNAseq_e10.5_Emin_LatNas_2500_K3 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#4 | 7.38e-04 | 721 | 13 | 4 | Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_2500_K4 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Facial Mesenchyne_top-relative-expression-ranked_2500_k-means-cluster#5 | 7.42e-04 | 722 | 13 | 4 | Facebase_RNAseq_e9.5_Facial Mesenchyne_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Paraxial Mesoderm_top-relative-expression-ranked_2500_k-means-cluster#3 | 7.73e-04 | 730 | 13 | 4 | Facebase_RNAseq_e8.5_Paraxial Mesoderm_2500_K3 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_2500_k-means-cluster#5 | 7.81e-04 | 732 | 13 | 4 | Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#5 | 8.26e-04 | 743 | 13 | 4 | Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_2500_k-means-cluster#2 | 8.43e-04 | 747 | 13 | 4 | Facebase_RNAseq_e9.5_Maxillary Arch_2500_K2 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#2 | 8.43e-04 | 747 | 13 | 4 | Facebase_RNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_2500_K2 | |
| CoexpressionAtlas | DevelopingGonad_e11.5_ovary + mesonephros_emap-3226_k-means-cluster#2_top-relative-expression-ranked_1000 | 8.91e-04 | 323 | 13 | 3 | gudmap_developingGonad_e11.5_ovary + mesonephros_k2_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_500_k-means-cluster#2 | 1.04e-03 | 79 | 13 | 2 | Facebase_RNAseq_e10.5_Maxillary Arch_500_K2 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_1000 | 1.04e-03 | 790 | 13 | 4 | gudmap_developingGonad_e16.5_epididymis_1000 | |
| CoexpressionAtlas | DevelopingGonad_e18.5_epididymis_emap-13166_top-relative-expression-ranked_1000 | 1.08e-03 | 799 | 13 | 4 | gudmap_developingGonad_e18.5_epididymis_1000 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_1000 | 1.09e-03 | 801 | 13 | 4 | gudmap_developingGonad_e14.5_ epididymis_1000 | |
| CoexpressionAtlas | DevelopingGonad_e12.5_ovary_emap-28876_top-relative-expression-ranked_1000 | 1.11e-03 | 804 | 13 | 4 | gudmap_developingGonad_e12.5_ovary_1000 | |
| CoexpressionAtlas | DevelopingGonad_e11.5_ovary + mesonephros_emap-3226_top-relative-expression-ranked_1000 | 1.17e-03 | 815 | 13 | 4 | gudmap_developingGonad_e11.5_ovary + mesonephros_1000 | |
| CoexpressionAtlas | facebase_RNAseq_e10.5_Emin_LatNas_2500 | 1.23e-03 | 1459 | 13 | 5 | facebase_RNAseq_e10.5_Emin_LatNas_2500 | |
| CoexpressionAtlas | facebase_RNAseq_e10.5_MandArch_2500 | 1.26e-03 | 1468 | 13 | 5 | facebase_RNAseq_e10.5_MandArch_2500 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_2500_k-means-cluster#3 | 1.64e-03 | 893 | 13 | 4 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_2500_K3 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_500 | 1.72e-03 | 406 | 13 | 3 | gudmap_developingGonad_e16.5_epididymis_500 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#2_top-relative-expression-ranked_500 | 1.89e-03 | 107 | 13 | 2 | gudmap_developingGonad_e14.5_ epididymis_500_k2 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_1000_k-means-cluster#3 | 2.05e-03 | 432 | 13 | 3 | Facebase_RNAseq_e10.5_Maxillary Arch_1000_K3 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_1000 | 2.39e-03 | 989 | 13 | 4 | Facebase_RNAseq_e10.5_Maxillary Arch_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Hind Brain Neural Epithelium_top-relative-expression-ranked_1000 | 2.40e-03 | 991 | 13 | 4 | Facebase_RNAseq_e8.5_Hind Brain Neural Epithelium_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Lateral Nasal Eminence_top-relative-expression-ranked_500 | 2.97e-03 | 492 | 13 | 3 | Facebase_RNAseq_e10.5_Lateral Nasal Eminence_500 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Flanking Eminence_top-relative-expression-ranked_500 | 3.08e-03 | 498 | 13 | 3 | Facebase_RNAseq_e10.5_Neural Epithelium Flanking Eminence_500 | |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 1.96e-07 | 186 | 13 | 4 | 03db813598b67b1e08f759758a1c2023396921fa | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid-nan|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.81e-05 | 182 | 13 | 3 | f8c73baaaca145e2efc48f10f636feb79c8fc779 | |
| ToppCell | droplet-Marrow-nan-3m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.87e-05 | 184 | 13 | 3 | 1154a5ad7b8512272b7476f949ddac350910bfb7 | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.90e-05 | 185 | 13 | 3 | 7adfa929930cfa795cbfbd9f1a0b439e08aa765d | |
| ToppCell | droplet-Bladder-nan|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.96e-05 | 187 | 13 | 3 | 663991a8afe652e92363b64bcbd68c14d0307f0e | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.22e-05 | 195 | 13 | 3 | 7796ea9247f4c63762f0de8490fed08b9717fa23 | |
| ToppCell | (5)_Dendritic_cell-(51)_cDC1|(5)_Dendritic_cell / shred on Cell_type and subtype | 5.67e-04 | 123 | 13 | 2 | d46cfdf8b3e561d8db33903207d5151cdb2a91d4 | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Myeloid-Neutrophil|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.62e-04 | 133 | 13 | 2 | 292ecfcadbaf15e0d34a3ab9bf511ab1065888bd | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Myeloid-neutrophil|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.62e-04 | 133 | 13 | 2 | f6e9a1301a3379847b215303a9b0c028841e2cc0 | |
| ToppCell | ILEUM-non-inflamed-(3)_MNP-(3)_moDC|(3)_MNP / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 6.82e-04 | 135 | 13 | 2 | b7a792a7c0c22d8b703509f134115f0e394d7de0 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c11-GNLY|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 8.63e-04 | 152 | 13 | 2 | 669d8f12fdb110ed72f4e5348b7b5350144a061c | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Myeloid-myeloid_leukocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.32e-04 | 158 | 13 | 2 | 91d265e95156f16459924d3e4dd11c180e164eee | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 9.44e-04 | 159 | 13 | 2 | 5ca96db4281abb5f646150ccf36adc66ab201c78 | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_B1|367C / Donor, Lineage, Cell class and subclass (all cells) | 9.67e-04 | 161 | 13 | 2 | f470b662566131dfe69a2fd01186ac8491196396 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Myeloid-macrophage/monocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.79e-04 | 162 | 13 | 2 | 93bd29c52846c3156b8b0d2e39c552373efdfe93 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.00e-03 | 164 | 13 | 2 | b6df1e67a5ce5f2d86f4e1420f4ee931f760bf4d | |
| ToppCell | nucseq-Immune-Hematopoietic-Granulocytic-Mast/Basophil|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.02e-03 | 165 | 13 | 2 | 640bb71e74a61df2fcb01ceeabe4c493ef836b21 | |
| ToppCell | nucseq-Immune-Hematopoietic-Granulocytic|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.02e-03 | 165 | 13 | 2 | 37615622c736e43260c38016e7c9e565ac97a3e8 | |
| ToppCell | nucseq-Immune-Hematopoietic|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.02e-03 | 165 | 13 | 2 | f3df74b5763130c71c0a482a3a23f6b22acc2892 | |
| ToppCell | COPD-Lymphoid-ILC_B|COPD / Disease state, Lineage and Cell class | 1.03e-03 | 166 | 13 | 2 | 7609671e453280c6e522e9f659c06aab8be81945 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Macrophage_Dendritic-Classical_Dendritic_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.03e-03 | 166 | 13 | 2 | 63dc58864268b4e7779e4c45155022556fc634f9 | |
| ToppCell | 10x_3'_v2v3-Neoplastic-Differentiated-like-AC-like-AC-like-D|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.05e-03 | 168 | 13 | 2 | 435ef2e4d702e978d54f9d1f5a047f39c691cc63 | |
| ToppCell | 368C-Lymphocytic-NK_cells-NK_cell_E|368C / Donor, Lineage, Cell class and subclass (all cells) | 1.06e-03 | 169 | 13 | 2 | 0d96c0b4fd26fbc0bf44ff7bed2936eebcc55b74 | |
| ToppCell | AT1-AT2_cells-Donor_03|World / lung cells shred on cell class, cell subclass, sample id | 1.06e-03 | 169 | 13 | 2 | 815474855a70498a74e52f6583113c63b7267a0c | |
| ToppCell | metastatic_Lymph_Node-Myeloid_cells-CD141+_DCs|Myeloid_cells / Location, Cell class and cell subclass | 1.06e-03 | 169 | 13 | 2 | a4204bdd75837f5fee9aaac459cb4c19ee2a7bf4 | |
| ToppCell | BAL-Control-Lymphocyte-B-Plasmablast|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.06e-03 | 169 | 13 | 2 | 9ab34f602d46ce87283d243b81621e8806504f43 | |
| ToppCell | BAL-Control-Lymphocyte-B-Plasmablast-Plasmablast|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.06e-03 | 169 | 13 | 2 | 89fbafdb4628ce7a90c50398870e0f8ee90cfd91 | |
| ToppCell | BAL-Control-Lymphocyte-B-Plasmablast-Plasmablast-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.06e-03 | 169 | 13 | 2 | 75d367eb35768d3063096e8866cea649dac3b1bd | |
| ToppCell | TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-4|TCGA-Liver / Sample_Type by Project: Shred V9 | 1.06e-03 | 169 | 13 | 2 | 0a3ba6b5d6cff9d3d7f56046063cfc3a37ae1156 | |
| ToppCell | BAL-Control-Lymphocyte-B-Plasmablast-Plasmablast-Plasmablast|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.08e-03 | 170 | 13 | 2 | 7dcb6319ba4d7b258dd0a17449d837800ef46ccc | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.08e-03 | 170 | 13 | 2 | 876b84740e15399bfff2b9c7f0b80fd759bbdb3f | |
| ToppCell | COVID-19-lung-MAST|lung / Disease (COVID-19 only), tissue and cell type | 1.08e-03 | 170 | 13 | 2 | e90f18e5462381b38e918442b38b1c8105291908 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.08e-03 | 170 | 13 | 2 | 1f8738acf439d893880db7e1fdc9b3615ca00c39 | |
| ToppCell | BAL-Control-Lymphocyte-B-Plasmablast-Plasmablast|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.08e-03 | 170 | 13 | 2 | 7377e59fba4bf97ba893ccf6b5e149b5152407be | |
| ToppCell | BAL-Control-Lymphocyte-B-Plasmablast|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.08e-03 | 170 | 13 | 2 | e18211029e9ffad54458fd921f455172aad407c7 | |
| ToppCell | Control-B_cell-Plasmablast|Control / Disease group,lineage and cell class （2021.01.30） | 1.09e-03 | 171 | 13 | 2 | c09afc4b111b2b5acca75177554f6364ee02d37c | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_NK-T_NK-NK_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 1.10e-03 | 172 | 13 | 2 | a126dacd94939851de1403d30f0b63eaad48bfa1 | |
| ToppCell | facs-Spleen-nan-24m-Lymphocytic-Cd3e_T_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.12e-03 | 173 | 13 | 2 | f2eeff86e7dc7f4e3c36f775777d56685d7096cf | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Macrophage_Dendritic-Classical_Dendritic_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.12e-03 | 173 | 13 | 2 | 73f858f2c45d19b9ec8d99ac02c91551790f670c | |
| ToppCell | LV-17._Lymphocyte|World / Chamber and Cluster_Paper | 1.12e-03 | 173 | 13 | 2 | 212f013ff761cbab24a537071739867c08c402a4 | |
| ToppCell | facs-Spleen-nan-24m-Lymphocytic-CD4-positive,_alpha-beta_T_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.13e-03 | 174 | 13 | 2 | 096bc6f1889f2bbadfe1e1a3eb6ae569aaa2ee7d | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c04-SOX5-TNFRSF1B|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.13e-03 | 174 | 13 | 2 | ebe6ce173ad12d4a2afa39f8d6185c0e4f97fb1e | |
| ToppCell | COPD-Lymphoid-ILC_A|COPD / Disease state, Lineage and Cell class | 1.15e-03 | 176 | 13 | 2 | 484452cb38fe4604f0910a068361ed461b5b0c21 | |
| ToppCell | CV-Severe-7|CV / Virus stimulation, Condition and Cluster | 1.15e-03 | 176 | 13 | 2 | 3de0c7d77210049e5616db21eed1490a17a5ec2d | |
| ToppCell | COVID-19-lung-MAST|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.15e-03 | 176 | 13 | 2 | 473c45a381ca109207d66ed1635668b391ea0e1f | |
| ToppCell | droplet-Heart-nan-3m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.15e-03 | 176 | 13 | 2 | 749b47eac5436fa34e0d243ffbc6f1897f4e431e | |
| ToppCell | BAL-Control-Lymphocyte-B|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.15e-03 | 176 | 13 | 2 | 7c1ecec45b5fe5e73cbce0fadca726ffd10c0316 | |
| ToppCell | facs-Spleen-nan-24m-Lymphocytic-CD8-positive,_alpha-beta_T_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.17e-03 | 177 | 13 | 2 | 0d894a14ddbb2734557743e9efdb89cee5c26769 | |
| ToppCell | CV-Severe-7|Severe / Virus stimulation, Condition and Cluster | 1.17e-03 | 177 | 13 | 2 | 82fdd6185b368f54f03de389427cbe3071d21a99 | |
| ToppCell | COVID-19-B_cells-Activated_B_cells|COVID-19 / group, cell type (main and fine annotations) | 1.17e-03 | 177 | 13 | 2 | 653bb62a3744d4024ab3186ee01d410ed62832a6 | |
| ToppCell | LA-17._Lymphocyte|World / Chamber and Cluster_Paper | 1.18e-03 | 178 | 13 | 2 | 34ec499d03cc198cfefa19a724d4c81974052f65 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.18e-03 | 178 | 13 | 2 | 01dafd19de04eff459253eaa9a35debf8f3deedf | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-B_cell-B_cell|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.19e-03 | 179 | 13 | 2 | fad1fbee002fcd424c03460d695559060ce41a3f | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-B_cell|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.19e-03 | 179 | 13 | 2 | 6d4e4b64e633b2ae8514ffa1e45829d6508dac54 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-B_cell-B_cell-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.19e-03 | 179 | 13 | 2 | 61a7cc01fae4115325fce0efaa5bacf8f9af5ba2 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Cortical_Collecting_Duct_Principal_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.21e-03 | 180 | 13 | 2 | 023ec0b080c8a5cd0f36e83c6b17d4be3c01edb5 | |
| ToppCell | droplet-Heart-nan-3m-Neuronal-cardiac_neuron|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.21e-03 | 180 | 13 | 2 | da723df348d7b8449bb1124f23fe6fa706412adb | |
| ToppCell | IPF-Lymphoid-B|World / Disease state, Lineage and Cell class | 1.21e-03 | 180 | 13 | 2 | 30f9398c9b784f49470847a025bac90687e997a1 | |
| ToppCell | (5)_Epithelial_cells-(5)_Glands_mucous|(5)_Epithelial_cells / Oesophagus cell shreds on cell class (v1) and cell subclass (v1) | 1.21e-03 | 180 | 13 | 2 | a4118adaf4b09e2ca01b662ed60e7bbf32a24d58 | |
| ToppCell | droplet-Heart-nan-3m-Neuronal|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.21e-03 | 180 | 13 | 2 | 5b146a94708b3c3610542a4d0925f3f7a2b19185 | |
| ToppCell | droplet-Heart-nan-3m-Neuronal-cardiac_neuron|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.21e-03 | 180 | 13 | 2 | 50758b1e7be2e43f83c10ab106900c067e61f5f7 | |
| ToppCell | COVID-19-kidney-NK|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.22e-03 | 181 | 13 | 2 | 8906ee8a7a1616dfe8c3b5c73988416641213629 | |
| ToppCell | LA-17._Lymphocyte|LA / Chamber and Cluster_Paper | 1.22e-03 | 181 | 13 | 2 | 3fd9f805fa46141b0fa7023ee5d8688d338635d5 | |
| ToppCell | LV-17._Lymphocyte|LV / Chamber and Cluster_Paper | 1.22e-03 | 181 | 13 | 2 | 81fafa69c8c240250a667a5f3b321e8be1b9a288 | |
| ToppCell | 3'-GW_trimst-1-SmallIntestine-Epithelial-neuro-epithelial-M/X_cells_(MLN/GHRL+)|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.22e-03 | 181 | 13 | 2 | af031661af28f99d906d8e013b4949133b44a2e6 | |
| ToppCell | facs-Spleen-nan-18m-Lymphocytic-CD4-positive,_alpha-beta_T_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.23e-03 | 182 | 13 | 2 | fbe5bdd642b86010dbef0a567b25c69c7335688f | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.23e-03 | 182 | 13 | 2 | bc8d621be57f76d718d9b0f11e023b0f4dcb668d | |
| ToppCell | Smart-seq2-spleen_(Smart-seq2)-lymphocytic-T_lymphocytic-type_I_NK_T_cell|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.23e-03 | 182 | 13 | 2 | 9d727ab84da8de33f1021b492c90d8b4c2a8ea23 | |
| ToppCell | IPF-Lymphoid-ILC_A|World / Disease state, Lineage and Cell class | 1.23e-03 | 182 | 13 | 2 | f91bb45baaec76cb3bb26eedbcf0709b2492e93f | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT_L6_FEZF2-Exc_L6_FEZF2_VWA2|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.23e-03 | 182 | 13 | 2 | 72e65a23cd36085bc880087d3cae92395de918a1 | |
| ToppCell | RA-17._Lymphocyte|RA / Chamber and Cluster_Paper | 1.23e-03 | 182 | 13 | 2 | 257a7847917b6ea1d60608183d90300bfd028758 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT_L6_FEZF2|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.23e-03 | 182 | 13 | 2 | 05c167158815bf25d509df59ab386e1990712765 | |
| ToppCell | Mild/Remission-B_intermediate-10|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.25e-03 | 183 | 13 | 2 | 278064c9f0582463b83bf156d34e77f60187613b | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_5|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.25e-03 | 183 | 13 | 2 | 274076a0978bce2bd53a1732045f18ef0f2d9985 | |
| ToppCell | IPF-Lymphoid-ILC_A|IPF / Disease state, Lineage and Cell class | 1.25e-03 | 183 | 13 | 2 | 49bfeaae13eb236f61a5486ee75c39789936bb8a | |
| ToppCell | COVID-19-B_cells|COVID-19 / group, cell type (main and fine annotations) | 1.25e-03 | 183 | 13 | 2 | 2c016bb59f131a0e821853b085289a3583f0a729 | |
| ToppCell | Control-T_cells-CD8+_T_cells|Control / group, cell type (main and fine annotations) | 1.27e-03 | 185 | 13 | 2 | 02ab64c0166c0646d1d4c6ed110ef0b75a1096d0 | |
| ToppCell | droplet-Marrow-nan-18m-Hematologic-hematopoietic_precursor_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.27e-03 | 185 | 13 | 2 | de353368f4f6a7a0a66e391d586879876fbe2734 | |
| ToppCell | 18-Distal-Epithelial-Neuroendocrine|Distal / Age, Tissue, Lineage and Cell class | 1.27e-03 | 185 | 13 | 2 | f8fc7b12b4e18d23d84e95488be93c4352d325f3 | |
| ToppCell | pdx|World / Sample and Cell Type and Tumor Cluster (all cells) | 1.29e-03 | 186 | 13 | 2 | de8e538c8767d41b8a52f5e58ba1affd4e7244c4 | |
| ToppCell | pdx-Tumor_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 1.29e-03 | 186 | 13 | 2 | 0b88a87158a9ca8de3bf40a4ff1687150707a5f0 | |
| ToppCell | Mild-Lymphoid-T-NK|Mild / Condition, Lineage, Cell class and cell subclass | 1.29e-03 | 186 | 13 | 2 | ed37a2df547661d22c1ed0b30cb1c19e489d9d0a | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-T_lymphocytic_-_developing-thymocyte|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.31e-03 | 188 | 13 | 2 | bcfc426b60d8e5a23a2360bfb68b32868fec9fbf | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_2-D175|Adult / Lineage, Cell type, age group and donor | 1.31e-03 | 188 | 13 | 2 | ec38def1fdbb34ed9b30244806975bd5a4370164 | |
| ToppCell | human_hepatoblastoma-NK.T_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 1.31e-03 | 188 | 13 | 2 | 71b7599e7e1d63cc0c8518c0501533755951d58f | |
| ToppCell | IPF-Lymphoid-NK|IPF / Disease state, Lineage and Cell class | 1.33e-03 | 189 | 13 | 2 | d92e880162450f8d01e4b8784eb625275cb8e03e | |
| ToppCell | Children_(3_yrs)-Immune-T_lymphocyte-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.33e-03 | 189 | 13 | 2 | df30478b288084a1bd48f660409dcc784040897c | |
| ToppCell | COVID-19-T_cells-CD8+_T_cells|COVID-19 / group, cell type (main and fine annotations) | 1.33e-03 | 189 | 13 | 2 | 2c018d6120f65f0b2704b483bc9da1c0984872e3 | |
| ToppCell | Control-Lymphoid-T_Cytotoxic|World / Disease state, Lineage and Cell class | 1.33e-03 | 189 | 13 | 2 | ee4c1d930534788a7759d92dc8ff9c62e6ee2301 | |
| ToppCell | COVID-19-T_cells-NK_cells|COVID-19 / group, cell type (main and fine annotations) | 1.33e-03 | 189 | 13 | 2 | b699152dfbb8cd8ed724e1e5a51838f29b681b62 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell-B_c04-SOX5-TNFRSF1B|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.34e-03 | 190 | 13 | 2 | ed100e271aac82806f59e0c613ccda63f59100c1 | |
| ToppCell | IPF-Lymphoid-T_Cytotoxic|IPF / Disease state, Lineage and Cell class | 1.34e-03 | 190 | 13 | 2 | e5d0186bfb416a3eda76ac12b9379650afb6f409 | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_B1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 1.36e-03 | 191 | 13 | 2 | 39ef8e1d7cc3ebb11717e8a55501515e3b72b177 | |
| ToppCell | COPD-Myeloid-cDC1|Myeloid / Disease state, Lineage and Cell class | 1.36e-03 | 191 | 13 | 2 | 3480e6d27dd4291765bbbb2acdb6a2e4f02c8085 | |
| ToppCell | Control-Lymphoid-T_Cytotoxic|Control / Disease state, Lineage and Cell class | 1.36e-03 | 191 | 13 | 2 | 03b5c5e0941c3402ab3f48cbf3da2a027d110421 | |
| ToppCell | COVID-19-lung-CD8+_T_cells|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.36e-03 | 191 | 13 | 2 | 543f8ae07cc2e6950c888115a5ca9445e3c0f618 | |
| ToppCell | COVID-19-T_cells-CD4+_T_cells|COVID-19 / group, cell type (main and fine annotations) | 1.36e-03 | 191 | 13 | 2 | 0646cca78e24aeb6baa9934d3c439b797c567997 | |
| ToppCell | Children_(3_yrs)-Immune-T_lymphocyte-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.36e-03 | 191 | 13 | 2 | c7be771543089fc94e5c62fd22f745189642aec3 | |
| ToppCell | COVID-19-T_cells|COVID-19 / group, cell type (main and fine annotations) | 1.36e-03 | 191 | 13 | 2 | 7f64add931b64b8d35836fa6bee9ebab593844d3 | |
| ToppCell | COVID-19-lung-AT2|lung / Disease (COVID-19 only), tissue and cell type | 1.36e-03 | 191 | 13 | 2 | 276455a64c2c3503d5048615762eb2ee37f0ac70 | |
| Drug | AC1L2E0P | 5.08e-07 | 307 | 13 | 5 | CID000019390 | |
| Drug | irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A | 2.73e-06 | 183 | 13 | 4 | 7498_DN | |
| Drug | 3,4-dimethoxy-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-phenylbenzenesulfonamide | 3.01e-06 | 5 | 13 | 2 | ctd:C575894 | |
| Drug | 1-chlorobutane | 1.08e-05 | 9 | 13 | 2 | CID000008005 | |
| Drug | AC1L1COZ | 1.66e-05 | 90 | 13 | 3 | CID000001996 | |
| Drug | TiNi | 2.28e-05 | 100 | 13 | 3 | CID000159408 | |
| Drug | 4,4'-DBP | 5.12e-05 | 19 | 13 | 2 | CID000007034 | |
| Drug | AC1Q68Z5 | 5.15e-05 | 386 | 13 | 4 | CID000000181 | |
| Drug | glutamin | 1.03e-04 | 461 | 13 | 4 | CID000000738 | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A | 1.17e-04 | 173 | 13 | 3 | 4458_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 1.19e-04 | 174 | 13 | 3 | 1659_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 1.25e-04 | 177 | 13 | 3 | 3227_DN | |
| Drug | Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A | 1.31e-04 | 180 | 13 | 3 | 4541_DN | |
| Drug | Neostigmine bromide [114-80-7]; Down 200; 13.2uM; PC3; HT_HG-U133A | 1.49e-04 | 188 | 13 | 3 | 6735_DN | |
| Drug | Perphenazine [58-39-9]; Down 200; 10uM; PC3; HG-U133A | 1.66e-04 | 195 | 13 | 3 | 1956_DN | |
| Drug | Ketotifen fumarate [34580-14-8]; Up 200; 9.4uM; HL60; HG-U133A | 1.71e-04 | 197 | 13 | 3 | 1583_UP | |
| Drug | Ciprofloxacin hydrochloride [93107-08-5]; Up 200; 10.8uM; HL60; HG-U133A | 1.71e-04 | 197 | 13 | 3 | 2022_UP | |
| Drug | Aztreonam [78110-38-0]; Down 200; 9.2uM; PC3; HT_HG-U133A | 1.74e-04 | 198 | 13 | 3 | 5110_DN | |
| Drug | Naproxen [22204-53-1]; Up 200; 17.4uM; MCF7; HT_HG-U133A | 1.74e-04 | 198 | 13 | 3 | 5457_UP | |
| Drug | Methoxy-6-harmalan [3589-73-9]; Down 200; 18.6uM; PC3; HT_HG-U133A | 1.76e-04 | 199 | 13 | 3 | 6355_DN | |
| Drug | cyclosarin | 1.76e-04 | 199 | 13 | 3 | CID000064505 | |
| Drug | Amodiaquin dihydrochloride dihydrate [6398-98-7]; Up 200; 8.6uM; HL60; HG-U133A | 1.79e-04 | 200 | 13 | 3 | 1570_UP | |
| Drug | CV-1 | 2.15e-04 | 213 | 13 | 3 | CID000130105 | |
| Drug | 5-(4-methylpiperazin-1-yl)-2-(2'-(3,4-dimethoxyphenyl)-5'-benzimidazolyl)benzimidazole | 2.20e-04 | 39 | 13 | 2 | ctd:C477187 | |
| Drug | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2.44e-04 | 41 | 13 | 2 | ctd:D019307 | |
| Drug | N-methylmesoporphyrin | 2.56e-04 | 42 | 13 | 2 | CID000444708 | |
| Drug | Androstenedione | 2.94e-04 | 45 | 13 | 2 | ctd:D000735 | |
| Drug | AC1ND2OB | 4.09e-04 | 265 | 13 | 3 | CID004568637 | |
| Drug | iclaprim | 5.58e-04 | 62 | 13 | 2 | CID000213043 | |
| Disease | RUBINSTEIN-TAYBI SYNDROME 1 | 1.79e-07 | 2 | 13 | 2 | C4551859 | |
| Disease | Menke-Hennekam syndrome | 1.79e-07 | 2 | 13 | 2 | cv:C5681632 | |
| Disease | Rubinstein-Taybi syndrome (is_implicated_in) | 1.79e-07 | 2 | 13 | 2 | DOID:1933 (is_implicated_in) | |
| Disease | Rubinstein-Taybi syndrome (implicated_via_orthology) | 1.79e-07 | 2 | 13 | 2 | DOID:1933 (implicated_via_orthology) | |
| Disease | RUBINSTEIN-TAYBI SYNDROME 1 | 1.79e-07 | 2 | 13 | 2 | 180849 | |
| Disease | Rubinstein-Taybi syndrome due to CREBBP mutations | 1.79e-07 | 2 | 13 | 2 | cv:C4551859 | |
| Disease | Rubinstein-Taybi syndrome | 1.79e-07 | 2 | 13 | 2 | cv:C0035934 | |
| Disease | Rubinstein-Taybi Syndrome | 1.79e-07 | 2 | 13 | 2 | C0035934 | |
| Disease | Adenoid Cystic Carcinoma | 1.05e-05 | 100 | 13 | 3 | C0010606 | |
| Disease | Squamous cell carcinoma | 2.01e-05 | 124 | 13 | 3 | C0007137 | |
| Disease | Adenocarcinoma of lung (disorder) | 9.11e-05 | 206 | 13 | 3 | C0152013 | |
| Disease | Carcinoma, Transitional Cell | 1.46e-04 | 41 | 13 | 2 | C0007138 | |
| Disease | Small cell carcinoma of lung | 2.53e-04 | 54 | 13 | 2 | C0149925 | |
| Disease | Diffuse Large B-Cell Lymphoma | 2.63e-04 | 55 | 13 | 2 | C0079744 | |
| Disease | Precursor Cell Lymphoblastic Leukemia Lymphoma | 3.23e-04 | 61 | 13 | 2 | C1961102 | |
| Disease | breast carcinoma (is_marker_for) | 3.78e-04 | 66 | 13 | 2 | DOID:3459 (is_marker_for) | |
| Disease | Papillary thyroid carcinoma | 6.41e-04 | 86 | 13 | 2 | C0238463 | |
| Disease | Squamous cell carcinoma of esophagus | 7.82e-04 | 95 | 13 | 2 | C0279626 | |
| Disease | Mammary Neoplasms, Human | 1.40e-03 | 525 | 13 | 3 | C1257931 | |
| Disease | Mammary Carcinoma, Human | 1.40e-03 | 525 | 13 | 3 | C4704874 | |
| Disease | Mammary Neoplasms | 1.42e-03 | 527 | 13 | 3 | C1458155 | |
| Disease | irritable bowel syndrome | 1.48e-03 | 131 | 13 | 2 | EFO_0000555 | |
| Disease | Breast Carcinoma | 1.50e-03 | 538 | 13 | 3 | C0678222 | |
| Disease | cannabis dependence | 1.57e-03 | 135 | 13 | 2 | EFO_0007191 | |
| Disease | Bladder Neoplasm | 1.68e-03 | 140 | 13 | 2 | C0005695 | |
| Disease | Malignant neoplasm of urinary bladder | 1.71e-03 | 141 | 13 | 2 | C0005684 | |
| Disease | prostate cancer (is_marker_for) | 2.08e-03 | 156 | 13 | 2 | DOID:10283 (is_marker_for) | |
| Disease | Leukemia, Myelocytic, Acute | 2.55e-03 | 173 | 13 | 2 | C0023467 | |
| Disease | alcohol use disorder (implicated_via_orthology) | 3.23e-03 | 195 | 13 | 2 | DOID:1574 (implicated_via_orthology) | |
| Disease | Mental Depression | 5.41e-03 | 254 | 13 | 2 | C0011570 | |
| Disease | Alcoholic Intoxication, Chronic | 6.00e-03 | 268 | 13 | 2 | C0001973 | |
| Disease | Cleft palate, cleft lip | 6.49e-03 | 279 | 13 | 2 | EFO_0003959, HP_0000175 | |
| Disease | Depressive disorder | 6.94e-03 | 289 | 13 | 2 | C0011581 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| QQQQQKQPHLAPLQM | 11 | Q8IVW6 | |
| PQQQQRMQHHMQQMQ | 2221 | Q09472 | |
| PPAMQQQQRMQQHLP | 2241 | Q92793 | |
| PQNHMNMINQQPNNL | 571 | Q96JK9 | |
| QLPSQMMVIQQKPRQ | 3951 | Q9Y6V0 | |
| KQMLNELMRQQNQHP | 1076 | Q15154 | |
| QQQMNAQHQPMNIFP | 1216 | Q99590 | |
| QKHQQLQQMRMQQPP | 526 | Q9UPN9 | |
| QQQQQMLQMRPGEIP | 976 | Q9Y6Q9 | |
| MPLMQTQQNLPHQTQ | 411 | O43556 | |
| MANPQMQQLIQRNPE | 206 | Q9UHD9 | |
| LNMQQHQPLTMQQPL | 431 | O94900 | |
| PMMQHLQEQQQQQMH | 331 | Q96PN7 |